Johnson & Johnson Reports P-I Data of Pasritamig + JNJ-9401 for Metastatic Castration-Resistant Prostate Cancer

Shots: Johnson & Johnson has reported first-in-human P-I data of pasritamig (KLK2xCD3) + JNJ-9401 (PSMAxCD28), dosed every 6wks., in heavily pretreated patients with mCRPC (n=144 enrolled) at SITC 2026 At the recommended regimen (n=15; median 4 prior lines), 73% achieved PSA reductions of ≥50% & 47% achieved ≥90% reductions, with 4 patients reaching undetectable PSA; all 7 patients with ≥90% reductions stayed on treatment for >6mos. without progression No Gr≥3 TRAEs, DLTs or discontinuations were reported at the recommended regimen; CRS (Gr1) occurred in 20% of patients with no ICANS; the combination is advancing to P-III Ref: PR Newswire  |   Image: Johnson & Johnson  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Johnson & Johnson Reports P-I Data of Pasritamig + JNJ-9401 for Metastatic Castration-Resistant Prostate Cancer appeared first on PharmaShots.